Protocol S of the Diabetic Retinopathy Clinical Research Network (clinicaltrials.gov NCT01489189) compares intravitreous ranibizumab vs panretinal photocoagulation (PRP) for managing proliferative diabetic retinopathy. Participants with 1 eye used in the study were randomly assigned to a dose of 0.5 mg ranibizumab (n = 102) or PRP (n = 114); participants with 2 eyes in the study (n = 89) had 0.5 mg of ranibizumab administered in 1 eye and PRP in the other eye (total 394 study eyes).
Hey, sailor! Get on board with the new nauticals inspired by the Normandy coast. These seaworthy (and wallet-friendly) picks are updated for fall with heavy fabrics and rich hues. By Adam Glassman